Table 3.
Outcomes of therapy for HCC with PVTT
| Study(year) | Treatments | Patients | Median OS(months) | 6-month(%) | 1-year(%) | 2-year(%) | 3-year(%) | 5-year(%) of Survival rates |
|---|---|---|---|---|---|---|---|---|
| Fan 2001 [20] | HR | 74 | 12 | NA | 53.9 | NA | 26.9 | 16.6 |
| TACE | 18 | 5 | NA | 22.2 | NA | 5.6 | 0 | |
| Fan 2003 [19] | HR | 19 | 10.3 | 45.9 | 14.2 | 0 | 0 | NA |
| TACE | 41 | 7.1 | 34.2 | 12.2 | 0 | 0 | NA | |
| Cheng 2005 [18] | HR | 7 | 8.0 (4.5-11.5) | NA | 14.3 | NA | NA | NA |
| TACE | 38 | 5.0 (4.4-5.6) | NA | 10.5 | NA | NA | NA | |
| Fan 2005 [21] | HR | 24 | 10.1 | 46.8 | 22.7 | 9.8 | 0 | NA |
| TACE | 53 | 7.3 | 34.6 | 11.8 | 0 | 0 | NA | |
| Zhou 2011 [25] | HR | 38 | 10 | NA | 47.0 | NA | 22.0 | NA |
| TACE | 10 | 7 | NA | 20.0 | NA | 0 | NA | |
| Peng 2012 [12] | HR | 201 | 20.0 ± 1.8 | NA | 42.0 | NA | 14.1 | 11.1 |
| TACE | 402 | 13.1 ± 0.6 | NA | 37.8 | NA | 7.3 | 0.5 | |
| Liu PH 2014 [22] | HR | 108 | 64 | NA | 84 | NA | 69 | 69 |
| TACE | 108 | 32 | NA | 71 | NA | 50 | 35 | |
| Liu K 2014 [17] | HR | 41 | 21.5 | NA | 70.1 | 40.8 | 16.7 | NA |
| TACE | 72 | 13.8 | NA | 44.8 | 17.4 | 7.5 | NA | |
| Ye 2014 [24] | HR | 90 | 8.2 | NA | 28 | 20 | 15 | NA |
| TACE | 86 | 7.0 | NA | 17.5 | 0 | 0 | NA | |
| Lee 2016 [13] | HR | 40 | 19.9 | NA | 64.7 | 58.3 | 49.9 | NA |
| TACE | 80 | 6.6 | NA | 46.2 | 15.4 | 7.7 | NA | |
| Zheng 2016 [1] | HR | 96 | NA | NA | 86.5 | NA | 60.4 | 33.3 |
| TACE | 134 | NA | NA | 77.6 | NA | 47.8 | 20.9 | |
| Wang 2016 [11] | HR | 745 | NA | NA | 49.1 | 29.1 | 18.3 | 9.5 |
| TACE | 604 | NA | NA | 27.6 | 11.3 | 6.8 | 4.6 |